Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 7:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–15 of 15 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Macula Edema Clear all
Completed Phase 1Phase 2 Interventional Results available

Ranibizumab 0.5mg and 2.0mg to Treat Diabetic Macular Edema in Patients With Poor Response to Bevacizumab

NCT01292798
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab
Drug
Lead sponsor
California Retina Consultants
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
5
States / cities
Bakersfield, California • Oxnard, California • Santa Barbara, California + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2016 · Synced Oct 20, 2026, 7:32 PM EDT
Completed No phase listed Observational

Describing Patient With DME, Their Patient Journey and Disease Progression

NCT05966753
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
221,004 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 19, 2024 · Synced Oct 20, 2026, 7:32 PM EDT
Not listed Phase 4 Interventional

Increase in Capillary Plexus Density Level Following the Use of Ozurdex for the Treatment of DME

NCT04038125
View directory record Official record
Conditions
Diabetic Macular Edema, Diabetic Retinopathy, Retinal Ischemia
Interventions
Ozurdex Drug Implant Product
Drug
Lead sponsor
Retina Macula Specialists of Miami, LLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
2
States / cities
North Miami Beach, Florida • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 18, 2020 · Synced Oct 20, 2026, 7:32 PM EDT
Completed No phase listed Observational

Outcomes of Diabetic Macula Edema Patients Switched to Aflibercept From Bevacizumab and/or Ranibizumab

NCT02000102
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Intravitreal Injection of Aflibercept
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 18, 2014 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

NCT03927690
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
LKA651, Lucentis
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Beverly Hills, California • Rancho Cordova, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

Ranibizumab for Edema of the Macula in Diabetes: Protocol 3 With High Dose - the READ 3 Study

NCT01077401
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
ranibizumab
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
13
States / cities
Beverly Hills, California • La Jolla, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 20, 2026, 7:32 PM EDT
Not listed Phase 1 Interventional

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

NCT04120636
View directory record Official record
Conditions
Macula Edema, Radiation Retinopathy, Branch Retinal Vein Occlusion, Epiretinal Membrane, Central Serous Retinopathy With Pit of Optic Disc, Commotio Retinae, Vitritis
Interventions
Episcleral Celecoxib
Drug
Lead sponsor
Targeted Therapy Technologies, LLC
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 20, 2026, 7:32 PM EDT
Terminated Not applicable Interventional Results available

Clinical Efficacy of Bevacizumab Combined With Navigated Laser in Patients With Clinically Significant Macula Edema

NCT02032238
View directory record Official record
Conditions
Clinically Significant Macular Edema
Interventions
laser photocoagulation
Device
Lead sponsor
OD-OS GmbH
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

The Ranibizumab for Edema of the mAcula in Diabetes-2 (READ-2) Study

NCT00407381
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Ranibizumab, Laser photocoagulation
Drug · Procedure
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
20
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Results available

TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)

NCT03093701
View directory record Official record
Conditions
Retinal Vein Occlusion, Macula Edema
Interventions
TLC399 (ProDex)
Drug
Lead sponsor
Taiwan Liposome Company
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
20
States / cities
Phoenix, Arizona • Arcadia, California • Beverly Hills, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 23, 2021 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Not applicable Interventional

Sub-Tenon Triamcinolone in the Prevention of Radiation-Induced Macular Edema

NCT00441662
View directory record Official record
Conditions
Melanoma
Interventions
Sub-Tenon triamcinolone 40mg
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 1, 2007 · Synced Oct 20, 2026, 7:32 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO

NCT01692938
View directory record Official record
Conditions
Age-Related Macular Degeneration, Geographic Atrophy, Diabetic Retinopathy, Macular Edema, Retinal Vein Occlusion, Central Serous Retinopathy, Pattern Dystrophy of Macula, Epiretinal Membrane, Macular Hole
Interventions
Not listed
Lead sponsor
Optos, PLC
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
3
States / cities
Fort Lauderdale, Florida • Baltimore, Maryland • McAllen, Texas
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 20, 2026, 7:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

NCT01284478
View directory record Official record
Conditions
Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Interventions
Dexamethasone Implant
Drug
Lead sponsor
Northern California Retina Vitreous Associates
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Mountain View, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 20, 2026, 7:32 PM EDT